Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 4,400,000 shares, a growth of 6.5% from the July 15th total of 4,130,000 shares. Approximately 6.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is presently 2.7 days.
Integra LifeSciences Stock Down 1.4 %
Integra LifeSciences stock traded down $0.30 during trading on Friday, hitting $21.56. 526,854 shares of the company were exchanged, compared to its average volume of 1,155,710. The company has a market capitalization of $1.70 billion, a P/E ratio of 43.12, a PEG ratio of 0.84 and a beta of 1.11. The business’s 50 day moving average is $27.69 and its 200 day moving average is $31.80. Integra LifeSciences has a 52 week low of $21.08 and a 52 week high of $45.42. The company has a current ratio of 3.39, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the prior year, the company posted $0.71 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. Analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Integra LifeSciences
Insider Transactions at Integra LifeSciences
In other news, Chairman Stuart Essig purchased 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 3.10% of the company’s stock.
Institutional Trading of Integra LifeSciences
A number of institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its stake in Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the period. Blue Trust Inc. increased its holdings in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares during the last quarter. Hexagon Capital Partners LLC raised its position in Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the period. CWM LLC boosted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the last quarter. Finally, Valley National Advisers Inc. bought a new position in shares of Integra LifeSciences during the 1st quarter valued at approximately $63,000. 84.78% of the stock is owned by hedge funds and other institutional investors.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
- Five stocks we like better than Integra LifeSciences
- 3 REITs to Buy and Hold for the Long Term
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Buy P&G Now, Before It Sets A New All-Time High
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How Can Investors Benefit From After-Hours Trading
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.